Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Chemoradiotherapy for Esophageal Adenocarcinoma
NCT00354679Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2006
- Primary completion
- Jun 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in esophageal adenocarcinoma (EAC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Evaluation of Safety and Toxicity at 2 years. Started Apr 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT00354679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00354679.